

STANDARD DECLARATION OF INTERESTS (DOI) FORM

Definitions:

“**Activity**” or “**Activities**” (capitalised ‘A’) means an activity or activities of or under the Group of Chief Scientific Advisors for instance in its formation as Coordination Group or in sub-groups, or that or those in relation thereto, for example, SAPEA Working Groups.

"**Conflict of interest**" means any situation where an individual has an interest that may compromise or be reasonably perceived to compromise the individual’s capacity to act independently and in the public interest when providing advice to the Commission in relation to Activities performed.

"**Immediate family member**" means the individual’s spouse, children and parents. "Spouse" includes a partner with whom the individual has a registered non marital regime. "Children" means the child(ren) the individual and the spouse have in common, the own child(ren) of the individual and the own child(ren) of the spouse.

"**Legal entity**" means any commercial business, industry association, consultancy, research institution or other enterprise whose funding is significantly derived from commercial sources. It also includes independent own commercial businesses, law offices, consultancies or similar.

"**Body**" means a governmental, international or non-profit organisation.

"**Meeting**" includes a series or cycle of meetings.

Please answer each of the questions below. If the answer to any of the questions is "yes", please briefly describe relevant interests and circumstances, as appropriate.

If you do not describe relevant interests and your DoI form is considered to be incomplete, or if declared interests are considered to constitute a Conflict of Interest, you may be excluded from all or part of the Activities.

First name: **Rebecca**

Family name: **Fitzgerald**

Date: **28 July 2021**

Description of the Activity: **Project Chair for SAPEA Cancer Screening project**

1 EMPLOYMENT CONSULTANCY AND LEGAL REPRESENTATION

	Within the past 5 years, were you employed or have you had any other professional relationship with a natural or legal entity, or held any non-remunerated post in a legal entity or other body with an interest in the field of the Activity in question?	yes	
--	---	------------	--

<i>1a</i>	<i>Employment</i>	<input checked="" type="checkbox"/>	
<i>1b</i>	<i>Consultancy, including services as an advisor</i>	<input checked="" type="checkbox"/>	
<i>1c</i>	<i>Non-remunerated post</i>	<input type="checkbox"/>	<input type="checkbox"/>
<i>1d</i>	<i>Legal representation</i>	<input type="checkbox"/>	<input type="checkbox"/>

<i>activity</i>	<i>time period (from... until month/year)</i>	<i>name of entity or body</i>	<i>description</i>
NIHR Research Professor	2012-2017	Hutchison-MRC Research Centre Cancer Cell Unit, Hutchison/MRC Research Centre, Cambridge	
Occasional consultancy and webinars given for Medtronic	2014 to present	Medtronic	Advice on Cytosponge-TFF3 diagnostic which they licensed from my research from the Medical Research Council
Research collaborations for ctDNA assays	2019-2021	Roche	Roche provided their assay for us to test via a grant application.
Research collaborations for ctDNA assays	2019-2021	Natera	Natera designed and performed ctDNA assays using their platform
Interim Director	December 2019-present	MRC Cancer Unit of the Hutchison Research Centre	The Medical Research Council Cancer aims to understand the biological processes governing the transition from normal

			epithelial homeostasis to cancer.
Cambridge Lead	March 2019-present	Cancer Research UK International Alliance Cancer Early Detection	The International Alliance for Cancer Early Detection (ACED) is a new £55 million partnership between Cancer Research UK, the Canary Center at Stanford University, the University of Cambridge, the Knight Cancer Institute at OHSU, University College London and the University of Manchester.
Co-Lead	January 2017-present	Cancer Research UK Early Detection Programme	A flagship initiative of the CRUK Cambridge Centre. It brings together basic, translational and clinical scientists, spanning a broad spectrum of disciplinary approaches and expertise in multiple cancer types.
Professor of Cancer Prevention	October 2014-present	University of Cambridge	
Honorary Consultant Gastroenterology & Honorary Consultant	2001-present	Addenbrooke's Hospital, Cambridge (Department of Oncology)	
Director of Studies in Medicine & College Lecturer in Medical Sciences	2002-present	Trinity College Cambridge	
Former Member of the Assembly of the EU Mission on Cancer	Dec 2020-Dec 2021	European Board for Mission on Cancer	The Mission Outline for Cancer has been developed for the European Commission (September 2020), and the Commission is currently preparing its implementation strategy focusing on: cancer

			prevention; diagnostics and treatment of cancer; quality of life of patients, survivors, families, and carers; and equitable access to these services across Europe
--	--	--	---

2 MEMBERSHIP OF MANAGING BODY, SCIENTIFIC ADVISORY BODY OR EQUIVALENT STRUCTURE

	Within the past 5 years, have you participated in the internal decision-making of a legal entity or other body with an interest in the field of Activities in question or have you participated in the works of a Scientific Advisory Body with voting rights on the outputs of that entity?	yes	no
--	---	------------	-----------

2a	<i>Participation in a decision-making process</i>		<input checked="" type="checkbox"/>	<input type="checkbox"/>
2b	<i>Participation in the work of a Scientific Advisory Body</i>		<input checked="" type="checkbox"/>	<input type="checkbox"/>
<i>Activity</i>	<i>Time period (from... until month/year)</i>	<i>Name of legal entity or body</i>	<i>Description</i>	
Screening Committee				
Member	2021-present	Department of Health (UK) Task and Finish Group	Task and Finish Group to advise on targeted and risk stratified screening	
Chair	Present	Supra-Regional Multi-Disciplinary Team Meeting (SMDT) for Oesophago-Gastric Cancer	Chairs the SMDT across serving four hospitals across East of England (Cambridge, Peterborough & Hinchingbrooke, West Suffolk) to ensure a uniform and high-quality service	
Former Member	2020-2021	European Board for Mission in Cancer	The Mission Outline for Cancer has been developed for the European Commission (September 2020), and the Commission is	

			currently preparing its implementation strategy focusing on: cancer prevention; diagnostics and treatment of cancer; quality of life of patients, survivors, families, and carers; and equitable access to these services across Europe.
Member	October 2020	Early Detection and Diagnosis Steering Committee to develop an Early Diagnosis RoadMap	This Roadmap, published in October 2020, has been heralded as a landmark report in the early detection and diagnosis of cancer with clear paths to progress with global relevance.

3 RESEARCH SUPPORT

	Within the past 5 years, have you, or the research entity (institute or department) to which you belong, received any support from a legal entity or other body with an interest in the field of Activities in question?	yes	no
--	---	------------	-----------

3a	<i>Research support, including grants, rents, sponsorships, fellowships, non-monetary support</i>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
----	---	-------------------------------------	--------------------------

<i>Activity</i>	<i>Time period (from... until month/year)</i>	<i>Name of legal entity or body</i>	<i>Description</i>
Funding from Medtronic for devices for Cytosponge screening trial BEST3	2015-2020	Medtronic	Funding for devices and antibody assays for BEST3 screening trial (published Lancet and declared 2020)

Programme grant	2021-2026	UK Medical Research Council Grant for Translational Research in Oesophageal cancer	£2.5M grant awarded
Programme grant	2020-2023	Project DELTA.	Integrated diagnostic solution for early detection of oesophageal cancer £650,000 awarded
Programme grant	2019-2024	National Institute of Health UK	The oral microbiome for the detection of Barrett's oesophagus £87,000 awarded
Programme grant	2018-2020	Cancer Research UK	Mechanistically informed phenotypic screening to advance new therapeutic treatments for oesophageal cancer patients £77,000 awarded
Programme grant	2017-2021	Rosetrees Trust	Developing a novel approach for early detection of oesophageal cancer £335,400 awarded
Programme grant	2017-2019	The Royal Society	Digistain meets Cytosponge; a new technology for oesophageal cancer screening £114,000 awarded
Programme grant	2016-2019	Cancer Research UK	Multidimensional molecular imaging for early cancer diagnosis £125,000 awarded
Programme grant	2015-2018	Cancer Research UK	Screening for squamous dysplasia and early

			squamous cancer using Cytosponge £200,000 awarded
--	--	--	--

4 FINANCIAL INTERESTS

	Do you have current investments in a legal entity with an interest in the field of Activities in question, including holding of stocks and shares, and which amounts to more than 10,000 EUR per legal entity or entitling you to a voting right of 5% or more in such legal entity?	yes	no
--	---	------------	-----------

4a	Shares	<input checked="" type="checkbox"/> comp	<input type="checkbox"/>
4b	Other stock	<input type="checkbox"/>	<input type="checkbox"/>

<i>Investment</i>	<i>Name of legal entity</i>	<i>Description</i>
Co-Founder shares currently 8%. No voting rights, no right of veto, no income	Cyted Ltd	Early Diagnosis company

5 INTELLECTUAL PROPERTY

	Do you have any intellectual property rights that might be affected by the outcome of the Activities in question?	yes	no
--	--	------------	-----------

5a	Patent, trademarks, or copyrights	<input checked="" type="checkbox"/>	<input type="checkbox"/>
5b	Others	<input type="checkbox"/>	<input type="checkbox"/>

<i>Intellectual property</i>	<i>Description</i>
------------------------------	--------------------

Patents related to Cytosponge and related assays for oesophageal screening	Patents related to Cytosponge and related assays for oesophageal screening- these have been licensed to Covidien (now Medtronic) in 2014
--	--

6 PUBLIC STATEMENTS AND POSITIONS

	<i>Within the past 5 years, have you provided any expert opinion or testimony in the field of Activities in question, for a legal entity or other body as part of a regulatory, legislative or judicial process? Within the past 5 years have you held an office or other position, paid or unpaid, where you represented interests or defended a public statement or position in the field of Activities in question?</i>	yes	no
--	--	-----	----

6a	For a legal entity or other body as part of a regulatory, legislative or judicial process	<input type="checkbox"/>	<input checked="" type="checkbox"/>
6b	Represented interests or defended an opinion	<input type="checkbox"/>	<input checked="" type="checkbox"/>

Activity	Time period (from... until month/year)	Name of legal entity or body	Description

7 INTERESTS OF IMMEDIATE FAMILY MEMBERS

yes

no

7a	To your knowledge, are there any interests of your immediate family members which could be seen as undermining your independence when providing advice to the Commission in the field of the Activities in question?	<input type="checkbox"/>	<input checked="" type="checkbox"/>
-----------	---	--------------------------	-------------------------------------

<i>Interests</i>	<i>Time period (from... until month/year)</i>	<i>Name of legal entity or body</i>	<i>Description</i>

7b	<i>If interests of your immediate family members are declared, it is your responsibility to inform them about the collection and publication of information on their interests included in the DoI and to provide them with the privacy statement attached to the guidance for filling in this DoI, and this at the latest when you file the DoI form with the Commission.</i>
-----------	--

8 OTHER RELEVANT INFORMATION

yes

no

8a	Are there any other elements that could be seen as undermining your independence when providing advice to the Commission in the field of the Activities in question?	<input type="checkbox"/>	<input checked="" type="checkbox"/>
-----------	---	--------------------------	-------------------------------------

Description:

I hereby declare on my honour that I have read the guidance for completing this form. I also declare on my honour that the information disclosed in this form is true and complete to the best of my knowledge.

Should there be any change to the above information, including as regards upcoming activities, I will promptly notify the competent department or entity and complete a new DoI form describing the changes in question.

I am informed that my personal data are stored, processed and published in accordance with the applicable data protection legislation.

I have been informed that this form may be shared with the European Commission and will be publicly available once the SAPEA report is published.

Date: _28 July 2021 _____

Signature: (signature removed for online publication)